Abilify Maintena Kit - (300, 400 mg/vial ; Extended-release Injectable Suspension)

Generic Name	Aripiprazole	Innovator	Otsuka
Dosage	300, 400 mg/vial ; Extended-release Injectable Suspension	Branded US Sales	More Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	Less Than 5
Final Approvals	None	Generic Launches	None
Indication	ABILIFY MAINTENA is an atypical antipsychotic indicated for the treatment of schizophrenia.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*****	*** \ ***	*** **, ****	*******	********* ********	******* *** **** *** **** ****
*** ******	** \ **	*** **, ****	*******	****	*** ****** *** ****
******	** \ **	*** **, ****	*******	****	*** ****** *** ****

Chronology Of Events